Srinivasan, D.; Arostegui, M.; Goebel, E.J.; Hart, K.N.; Aykul, S.; Lees-Shepard, J.B.; Idone, V.; Hatsell, S.J.; Economides, A.N.
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva. Biomolecules 2024, 14, 101.
https://doi.org/10.3390/biom14010101
AMA Style
Srinivasan D, Arostegui M, Goebel EJ, Hart KN, Aykul S, Lees-Shepard JB, Idone V, Hatsell SJ, Economides AN.
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva. Biomolecules. 2024; 14(1):101.
https://doi.org/10.3390/biom14010101
Chicago/Turabian Style
Srinivasan, Dushyanth, Martin Arostegui, Erich J. Goebel, Kaitlin N. Hart, Senem Aykul, John B. Lees-Shepard, Vincent Idone, Sarah J. Hatsell, and Aris N. Economides.
2024. "How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva" Biomolecules 14, no. 1: 101.
https://doi.org/10.3390/biom14010101
APA Style
Srinivasan, D., Arostegui, M., Goebel, E. J., Hart, K. N., Aykul, S., Lees-Shepard, J. B., Idone, V., Hatsell, S. J., & Economides, A. N.
(2024). How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva. Biomolecules, 14(1), 101.
https://doi.org/10.3390/biom14010101
